MX2020005008A - Vectores virales que comprenden regiones de codificación de la proteína retinol deshidrogenasa 12 (rdh12) y métodos de tratamiento de distrofias retinianas. - Google Patents

Vectores virales que comprenden regiones de codificación de la proteína retinol deshidrogenasa 12 (rdh12) y métodos de tratamiento de distrofias retinianas.

Info

Publication number
MX2020005008A
MX2020005008A MX2020005008A MX2020005008A MX2020005008A MX 2020005008 A MX2020005008 A MX 2020005008A MX 2020005008 A MX2020005008 A MX 2020005008A MX 2020005008 A MX2020005008 A MX 2020005008A MX 2020005008 A MX2020005008 A MX 2020005008A
Authority
MX
Mexico
Prior art keywords
rdh12
methods
protein
treatment
viral vectors
Prior art date
Application number
MX2020005008A
Other languages
English (en)
Spanish (es)
Inventor
Debra A Thompson
Robin R Ali
Alexander J Smith
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX2020005008A publication Critical patent/MX2020005008A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01105—Retinol dehydrogenase (1.1.1.105)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2020005008A 2017-11-15 2018-11-15 Vectores virales que comprenden regiones de codificación de la proteína retinol deshidrogenasa 12 (rdh12) y métodos de tratamiento de distrofias retinianas. MX2020005008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762586624P 2017-11-15 2017-11-15
PCT/US2018/061319 WO2019099696A1 (en) 2017-11-15 2018-11-15 Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies

Publications (1)

Publication Number Publication Date
MX2020005008A true MX2020005008A (es) 2020-11-06

Family

ID=66431192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005008A MX2020005008A (es) 2017-11-15 2018-11-15 Vectores virales que comprenden regiones de codificación de la proteína retinol deshidrogenasa 12 (rdh12) y métodos de tratamiento de distrofias retinianas.

Country Status (27)

Country Link
US (2) US20190142909A1 (enExample)
EP (2) EP4364803A3 (enExample)
JP (2) JP2021502978A (enExample)
KR (1) KR102704296B1 (enExample)
CN (2) CN117752822A (enExample)
AU (1) AU2018367606B2 (enExample)
BR (1) BR112020009828A2 (enExample)
DK (1) DK3710590T3 (enExample)
EA (1) EA202091194A1 (enExample)
ES (1) ES2983990T3 (enExample)
FI (1) FI3710590T3 (enExample)
HR (1) HRP20241073T1 (enExample)
HU (1) HUE068393T2 (enExample)
IL (2) IL308645B1 (enExample)
LT (1) LT3710590T (enExample)
MA (1) MA50914A (enExample)
MX (1) MX2020005008A (enExample)
MY (1) MY204271A (enExample)
PH (1) PH12020551319A1 (enExample)
PL (1) PL3710590T3 (enExample)
PT (1) PT3710590T (enExample)
RS (1) RS65881B1 (enExample)
SG (1) SG11202004527YA (enExample)
SI (1) SI3710590T1 (enExample)
SM (1) SMT202400321T1 (enExample)
WO (1) WO2019099696A1 (enExample)
ZA (1) ZA202003416B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102526506B1 (ko) 2016-07-08 2023-05-03 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물
WO2022232249A1 (en) * 2021-04-27 2022-11-03 The Trustees Of Columbia University In The City Of New York Methods and compositions to regulate cholesterol efflux to prevent, treat, or cure macular degeneration
CN115725659A (zh) * 2022-04-01 2023-03-03 首都医科大学附属北京同仁医院 一种应用视网膜原位基因编辑制作非人灵长类动物先天性黑矇模型的方法
CN118453915A (zh) * 2024-04-29 2024-08-09 中国医学科学院北京协和医院 一种针对rdh12突变的基因治疗药物
CN119432856B (zh) * 2024-12-30 2025-08-12 云舟生物科技(广州)股份有限公司 核酸分子、病毒颗粒及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
SG10201800541SA (en) * 2010-04-23 2018-03-28 Univ Florida Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
WO2012167109A2 (en) * 2011-06-03 2012-12-06 Massachusetts Eye & Ear Infirmary Rpgrip1 gene therapy for leber congenital amaurosis
JP6199965B2 (ja) * 2012-07-11 2017-09-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｒｐｇｒｘ連鎖性網膜変性のａａｖ媒介型遺伝子治療
AU2015252797C1 (en) * 2014-05-02 2021-04-22 Genzyme Corporation AAV vectors for retinal and CNS gene therapy
GB201412011D0 (en) 2014-07-04 2014-08-20 Ucl Business Plc Treatments
HRP20241154T1 (hr) * 2014-07-24 2024-11-22 Massachusetts Eye & Ear Infirmary Rpgr genska terapija za pigmentnu retinopatiju
AU2016228751B2 (en) * 2015-03-11 2022-01-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
WO2016176690A2 (en) * 2015-04-30 2016-11-03 The Trustees Of Columbia University In The City Of New York Gene therapy for autosomal dominant diseases
KR102526506B1 (ko) 2016-07-08 2023-05-03 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물

Also Published As

Publication number Publication date
LT3710590T (lt) 2024-09-25
MA50914A (fr) 2020-09-23
AU2018367606B2 (en) 2024-08-29
HUE068393T2 (hu) 2024-12-28
KR102704296B1 (ko) 2024-09-05
JP2021502978A (ja) 2021-02-04
ES2983990T3 (es) 2024-10-28
BR112020009828A2 (pt) 2020-11-17
IL274609A (en) 2020-06-30
CA3082586A1 (en) 2019-05-23
ZA202003416B (en) 2024-10-30
EP3710590A1 (en) 2020-09-23
US20190142909A1 (en) 2019-05-16
IL274609B1 (en) 2024-01-01
EA202091194A1 (ru) 2020-08-14
KR20200088385A (ko) 2020-07-22
JP2023133434A (ja) 2023-09-22
IL308645B1 (en) 2025-09-01
SMT202400321T1 (it) 2024-11-15
SG11202004527YA (en) 2020-06-29
US20230190884A1 (en) 2023-06-22
IL274609B2 (en) 2024-05-01
IL308645A (en) 2024-01-01
MY204271A (en) 2024-08-20
CN111886340A (zh) 2020-11-03
RS65881B1 (sr) 2024-09-30
SI3710590T1 (sl) 2024-10-30
PL3710590T3 (pl) 2024-10-21
EP3710590B1 (en) 2024-07-17
FI3710590T3 (fi) 2024-08-06
CN117752822A (zh) 2024-03-26
DK3710590T3 (da) 2024-08-12
AU2018367606A1 (en) 2020-06-25
EP4364803A2 (en) 2024-05-08
JP7615238B2 (ja) 2025-01-16
EP3710590A4 (en) 2021-06-23
WO2019099696A1 (en) 2019-05-23
HRP20241073T1 (hr) 2024-11-08
EP4364803A3 (en) 2024-06-05
PH12020551319A1 (en) 2021-09-01
PT3710590T (pt) 2024-08-09

Similar Documents

Publication Publication Date Title
MX2020005008A (es) Vectores virales que comprenden regiones de codificación de la proteína retinol deshidrogenasa 12 (rdh12) y métodos de tratamiento de distrofias retinianas.
PE20211419A1 (es) Vectores virales recombinantes y acidos nucleicos para producirlos
MX2023013435A (es) Composiciones y metodos para expresar otoferlina.
SA520420518B1 (ar) تبديل الانتحاء النسيجي للفَيروسات المُرتَبِط بالفَيروس الغُدِّيّ
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
CL2019000167A1 (es) Novedosas proteínas de la cápside del virus adenoasociado.
BR112018072849A2 (pt) capsídeos variantes de vírus adeno associado e métodos de uso
MX2021013486A (es) Viriones de virus adenoasociados con capside variante y metodos para su uso.
EP4491733A3 (en) Modulation of aav vector transgene expression
MX376190B (es) PARTÍCULAS DE rAAV QUE CODIFICAN miR-708 Y USOS DEL MISMO.
PH12018500594A1 (en) Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
BR112017005892A2 (pt) variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
WO2016130589A3 (en) VARIANT RNAi
CO2023000156A2 (es) Administración de vectores de virus adenoasociado para distrofias musculares
NZ726316A (en) Adenoassociated virus vectors for the treatment of lysosomal storage disorders
EA201791971A1 (ru) Онколитический аденовирус, кодирующий белок b7
EA201791936A8 (ru) Рекомбинантные конструкции glut1 аденоассоциированного вирусного вектора и способы восстановления экспрессии glut1 на их основе
AR118850A1 (es) Composiciones útiles en el tratamiento de leucodistrofia metacromática
MX2021010356A (es) SUMINISTRO DE ß-SARCOGLICANO MEDIANTE VECTORES DE VIRUS ADENOASOCIADO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR.
MX2025008949A (es) Arni variante
MX2022004352A (es) Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c.
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
BR112016022854A2 (pt) método para tratar, aliviar ou proteger (prevenir), diminuir o progresso ou reverter uma doença, método para tratar, aliviar ou proteger (prevenir) uma doença, uso, e, ácido nucleico ou gene
AU2019286386A8 (en) Recombinant AAV vectors and methods of using the same